Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Profound Medical ( (TSE:PRN) ).
Profound Medical Corp., a commercial-stage medical device maker of AI-powered, MRI-guided, incision-free therapies, is expanding its footprint in prostate care with its TULSA-PRO platform for prostate cancer and benign prostatic hyperplasia, and its Sonalleve system for non-surgical treatment of bone metastases and gynecologic conditions. The company’s technologies are approved in major global markets and are designed to improve clinical precision and patient recovery by using real-time MRI guidance.
Profound announced that Texas Prostate, led by Dr. James Cochran at Dallas Medical Center, has completed its 100th TULSA Procedure, marking a key adoption milestone for the company’s prostate therapy technology. Texas Prostate’s shift from a private-pay to a Medicare-based model via collaboration with Dallas Medical Center drove a reported 500% increase in TULSA Procedure volumes, highlighting how a hospital-partnered reimbursement structure can accelerate uptake, broaden patient access, and potentially strengthen Profound’s competitive position in next-generation prostate care.
Dr. Cochran cited TULSA’s MRI guidance and real-time thermography as enabling treatment of a wider range of prostate disease with improved safety and precision compared with focal HIFU, while offering benefits such as no procedural blood loss, no overnight hospital stay, and fewer side effects. Profound’s leadership framed the Texas Prostate model as a blueprint for other urology practices seeking to integrate TULSA into mainstream prostate care, underscoring growing physician interest and regional demand from Texas and surrounding states.
The most recent analyst rating on (TSE:PRN) stock is a Hold with a C$8.50 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Spark’s Take on PRN Stock
According to Spark, TipRanks’ AI Analyst, PRN is a Neutral.
The score is held down primarily by weak financial performance (large losses and significant cash burn) and bearish technicals (downtrend across key moving averages with negative momentum). The earnings call adds support via credible growth/profitability targets, reimbursement and pipeline tailwinds, while valuation remains constrained by ongoing losses and no stated dividend.
To see Spark’s full report on PRN stock, click here.
More about Profound Medical
Profound Medical Corp. is a commercial-stage medical device company specializing in AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. Its flagship TULSA-PRO platform delivers MRI-guided prostate therapy for cancer and benign prostatic hyperplasia, while its Sonalleve system provides non-surgical, MRI-guided treatment for pain palliation and gynecologic conditions across major global markets.
By leveraging real-time MRI guidance, Profound’s technologies are designed to enhance clinical confidence, procedural control, and patient outcomes, enabling personalized, minimally invasive treatment strategies. The company focuses on replacing surgical and radiation-based interventions with precise, image-guided therapies that reduce blood loss, hospital stays, and common side effects such as urinary incontinence and erectile dysfunction.
Average Trading Volume: 20,761
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$319.2M
Find detailed analytics on PRN stock on TipRanks’ Stock Analysis page.